You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Computer-based Prescription Opioid Abuse Prevention for Adolescents
SBC: HEALTHSIM, INC. Topic: R42DESCRIPTION provided by applicant Recreational use of prescription opioids among adolescents is a significant and growing public health concern and has been referred to as an emerging epidemic in the U S Although a number of science based interactive drug abuse prevention programs exist focused on preventing use of non prescription drugs among youth to our knowledge no science based inter ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Fluorescence Image-Guided Near Infrared (NIR) Photodynamic Therapy (PDT) Agent
SBC: PHOTOLITEC LLC Topic: 102DESCRIPTION provided by applicant Photolitecandapos s patented technology is focused on developing improved agents for tumor imaging image guided surgery and or photodynamic therapy PDT The proposed STTR proposal includes fluorescence image guided PDT a andquot See and Treatandquot approach The fluorescence imaging compound with long wavelength absorption near nm should be extremel ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
A Rapid assay for RNA targeted drugs: Instrumentation Supplement
SBC: NUBAD LLC Topic: 300DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Assessing the Bite Counter as a Tool for Food Intake Monitoring: Phase II
SBC: BITE TECHNOLOGIES, LLC Topic: 300DESCRIPTION provided by applicant Self monitoring has been described as the andquot cornerstone of the behavioral treatment of obesityandquot Consistent self monitoring of energy intake is associated with improved dietary adherence and weight loss and maintenance The problem is that individuals are notoriously bad at self monitoring their intake and suffer from an underreporting bias The s ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of a new approach to screening for language impairments
SBC: PANTHER TECHNOLOGY Topic: NIDCDDESCRIPTIONprovided by applicantThis Small Business Technology and TransferSTTRFast Track proposal focuses on the translation of innovative research protocols for diagnosing Specific Language ImpairmentSLIinto an innovativeeasy touse app based screener with high potential for private sector commercializationSLI is a form of language impairment with no known causewith a strong research baseBecause ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
A Quantitative Optical Sensor to Monitor Tumor Vascular Physiology
SBC: Zenalux Biomedical, Inc. Topic: 102DESCRIPTION provided by applicant In there were new cases of head and neck cancers HNC in the United States Early detection of new and locally recurrent cancers is clinically important to reduce not only cancer related mortality but also treatment associated morbidity as it impacts multiple organ functions including respiration olfaction hearing eating swallowing and speak ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p
SBC: AGILE SCIENCES, INC. Topic: NIAIDDESCRIPTION provided by applicant The leading cause of mortality in patients with cystic fibrosis CF is pulmonary failure from lung infections and the predominant organism isolated from these infections is the bacterium Pseudomonas aeruginosa Lung infections of CF patients persist over the lifetime of the patients and are impossible to eradicate due to the ability of bacteria to form biofi ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Reversal of Myocardial Infarction by Localized Stimulation
SBC: Micro Vide, LLC Topic: NHLBIDESCRIPTION provided by applicant Heart attacks i e myocardial infarction or MI occur in more than million patients annually Advances in pharmacological therapy have dramatically improved survival following the initial MI Consequently the number of patients with previous MI continues to increase and as a result put in jeopardy millions of patients for development of heart failure I ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Web-Based Infrastructure for Comparison and Validation of Image Computing Methods
SBC: KITWARE INC Topic: 101DESCRIPTION provided by applicant We propose to develop the infrastructure for and deploy a commercial installation of an Algorithm Evaluation Service AES The service will help bridge the gap between algorithm researchers and commercial product developers It will assist commercial company in determining which medical image analysis and informatics algorithms they should integrate into t ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
HUMAN MONOCOLONAL ANTIBODIES FOR CNS REMYELINATION
SBC: Acorda Therapeutics, Inc. Topic: N/ADESCRIPTION (provided by applicant): The primary goal of the current research will be to select the best recombinant form of one of two naturally occurring human igM antibodies demonstrated to stimulate remyelination to further develop for clinical testing in inflammatory demyelinating disease, such as MS. These antibodies, designated sHIgM22 and sHIgM46, were isolated by the Rodriquez laboratory ...
STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health